Sodium-Glucose Cotransporter-2 Inhibitors Across the Glycemic Spectrum: Cardiovascular and Renal Outcomes With Mechanistic Insights.

Although the reduction in CV death or HF events did not reach statistical significance (HR 0.69; 95% CI 0.45-1.08), patients experienced clinically meaningful improvements in health status, reflected by an increase of 4.45 points in the Kansas City Cardiomyopathy Questionnaire total symptom score (KCCQ-TSS).

also in 111,027 other papers